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Q What effects—if any—does  
marijuana use during pregnancy 
have on the fetus or child?
 The effects are unclear. Mar-i 
 juana use during pregnancy is 
associated with clinically unimportant 
lower birth weights (growth differences of 
approximately 100 g), but no differences 
in preterm births or congenital anoma-
lies (strength of recommendation [SOR]: 
B, prospective and retrospective cohort 
studies with methodologic flaws). 
Similarly, prenatal marijuana use isn’t 
associated with differences in neurodevel-
opmental outcomes (behavior problems, 
intellect, visual perception, language, or 
sustained attention and memory tasks) at 
birth, in the neonatal period, or in child-
hood through age 3 years. However, it 
may be associated with minimally lower 
verbal/quantitative IQ scores (1%) at age 
6 years and increased impulsivity and hy-
peractivity (1%) at 10 years. Prenatal use 
isn’t linked to increased substance use at 
age 14 years (SOR: B, conflicting long-term 
prospective and retrospective cohort stud-
ies with methodologic flaws). 
Evidence summary 
A large systematic review of prospective and 
retrospective cohort studies found little or 
no effect of maternal marijuana use on birth 
weight, stillbirths, preterm births, or congeni-
tal anomalies (TABLE1-8). Some studies found 
lower birth weights and some found higher 
birth weights. The authors couldn’t perform 
a meta-analysis because of heterogeneity, 
but estimated a clinically insignificant differ-
ence of 100 g. Most studies were limited by 
failure to account for concurrent maternal 
tobacco smoking. 
Moreover, all studies used interview data 
to determine maternal prenatal marijuana 
use, which can be subject to large recall bias. 
A multicenter prospective study of 585 preg-
nant women that compared interview data 
with serum screening to identify tetrahydro-
cannabinol (THC) found poor correlation be-
tween history and laboratory validation, for 
example.1 Only 31% of pregnant women with 
positive THC testing self-reported marijuana 
use (31% sensitivity), and only 43% of women 
who reported marijuana use had a positive 
THC screen (43% specificity). Most studies 
didn’t quantify marijuana use well and didn’t 
associate use with trimester of exposure. 
The authors also point out that marijuana 
potency has increased substantially since the 
1980s when many of the studies were done 
(THC content was 3.2% in 1983 and 13% in 
2008); prenatal marijuana use in the present 
day may expose the fetus to larger amounts 
of THC.1
A 2016 retrospective cohort study of 
56 mothers who reported prenatal marijuana 
use found no differences in preterm birth, 
low birth weight, or Apgar scores.2
Neurodevelopmental effects on infants,  
long-term effects on children, teens
Three prospective cohort studies evaluated 
neurodevelopmental outcomes in neonates 
and infants, and 2 studies continued to follow 
children into adolescence.1,3  All found essen-
tially no differences associated with prenatal 
marijuana at birth, throughout infancy, and 
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through age 3 years. The studies had the same 
limitations as those described previously 
(potential recall bias for identifying which 
children were exposed to marijuana prena-
tally and poorly quantified marijuana use not 
well-associated with trimester of exposure). 
The Ottawa Prenatal Prospective Study 
(OPPS) examined 140 low-risk pregnancies in 
white women of higher socioeconomic status 
who used marijuana during pregnancy.1,3-7 
Investigators considered: socioeconomic 
status, standard demographics, obstetric his-
tory, and use of other drugs, tobacco, and 
alcohol. Using a standardized newborn as-
TABLE
Prenatal marijuana use and outcomes at birth and beyond*
Outcome Number of cohort 
studies (type)
Number of women 
reporting marijuana 
use during pregnancy
Findings (compared with nonusers) Comments
Birth weight1,2 12 (prospective) 4026 Approximately 100 g less Most studies consid-
ered socioeconomic 
status, standard  
demographics,  
obstetric history, 
use of other drugs, 
tobacco, alcohol8 (retrospective) 7573
Preterm birth1,2 7 (prospective) 2524 Most studies found no association Same as above
7 (retrospective) 3175
Major congenital  
anomalies1
2 (prospective) 1338 No association Same as above
2 (retrospective) 1638
Neurodevelopment  
(neonatal)1,3
2 (prospective) 704 No significant associations with 
differences in newborn behavior
Same as above
Neurodevelopment  
(infancy to age 3 yrs)1,3
3 (prospective) 924 Conflicting associations with 
development: “advanced motor 
skills” (OPPS), “lower memory and 
verbal scores” (MHPCD), and “no  
differences” (Gen-R) 
High drop-out rate 
with total (N=115) at 
age 3 yr
Neurodevelopment  
(school age, 5 or 6 yrs)4,5
2 (prospective) 63 OPPS: No association with  
cognitive or language  
differences 
MHPCD: 5%-10% differences in 
verbal and/or quantitative com-
ponents of Stanford-Binet IQ test, 
comparing marijuana use of  
≥1 time/day vs <1 time/day 
MHPCD: Authors 
estimated that 10% 
of score differences 
were attributable 
to marijuana, using 
statistical compensa-
tion for differences in 
socioeconomic status
Neurodevelopment 
(age 9-12 yrs)6,7
2 (prospective) 54 OPPS: No association with  
impulsivity or hyperactivity
MHPCD: Association with 10% 
greater scores for impulsivity and 
hyperactivity among children  
exposed to heaviest prenatal use
MHPCD: Authors 
estimated that 10% 
of score difference 
was attributable to 
marijuana, using 
statistical compensa-
tion for differences in 
socioeconomic status 
Neurodevelopment 
(age 14 yrs)8
1 (prospective) 79 MHPCD: No significant associa-
tion between maternal prenatal 
marijuana use and marijuana use 
by adolescent children 
Gen-R, Generation R study;1-3 MHPCD, Maternal Health Practices and Child Development study;1-5,7,8 OPPS, Ottawa Prenatal Prospective Study.1-4,6
*All data about frequency of use are from maternal history by interview or questionnaire.
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Marijuana  
potency has 
increased  
substantially 
since the 1980s, 
when many of 
the studies were 
done. (THC  
content was 
3.2% in 1983 
and 13% in 
2008.) 
sessment scale, they found subtle behavioral 
differences at one week but not 9 days. Inves-
tigators evaluated children again at 3 years 
of age, school entry (5 or 6 years), and 9 to 
12 years. 
The Maternal Health Practices and 
Child Development study (MHPCD) of 
564 high-risk pregnancies in predominantly 
minority women of low socioeconomic status 
followed infants from birth through 14 years 
of age.1,3-5,7,8 It found some small differences 
in outcomes among children exposed to mar-
ijuana prenatally. Of note, when investigators 
evaluated marijuana use at age 14 years, they 
compared adolescent self-report history with 
urine THC testing (specificity 78%).
The MHPCD study was limited because, 
compared with the nonusing group, moth-
ers who used marijuana were also 20% to 
25% more likely to be single and poor, to live 
in poorer quality homes, and to use alcohol, 
tobacco, and other drugs. Investigators used 
statistical modeling to account for these en-
vironmental differences and estimated that 
10% of the difference in outcomes was attrib-
utable to prenatal marijuana exposure.
The Generation R study (Gen R) enrolled 
220 lower-risk pregnancies in multiethnic 
European women of higher socioeconomic 
status, followed children to 3 years of age, and 
found no marijuana-associated differences 
in any parameter.1,3,4 The final assessment in-
cluded only 51 children.
Recommendations
The American College of Obstetricians and 
Gynecologists (ACOG) recommends screen-
ing all women for tobacco, alcohol, and drug 
use (including marijuana) during early preg-
nancy.9  Women who report marijuana use 
should be counseled regarding potential 
adverse consequences to fetal health and be 
encouraged to discontinue use. 
ACOG says that insufficient data exist to 
evaluate the effects of marijuana use on in-
fants during lactation and breastfeeding and 
recommends against it. 
The American Society of Addiction Med-
icine also recommends screening pregnant 
women for drug use and making appropriate 
referrals for substance use treatment.10             JFP
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